يعرض 1 - 10 نتائج من 48 نتيجة بحث عن '"Diphenoxylate Hydrochloride"', وقت الاستعلام: 0.89s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
  3. 3

    المصدر: Pharmaceutical Biology, Vol 59, Iss 1, Pp 1452-1463 (2021)
    Pharmaceutical Biology
    article-version (VoR) Version of Record

  4. 4
  5. 5
    تقرير

    المؤلفون: Puma Biotechnology, Inc.

    المساهمون: Jo Chien, Associate Clinical Professor of Medicine

    المصدر: Slamon DJ, Clark GM, Wong SG, Lev WJ, Ullrh A, McGue WL. Human breast cancer: correlatn of relapse and surval wh amplatn of the HER-2/neu oncogene. Scnce. 1987 Jan 9;235(4785):177-82. do 10.1126/scnce.3798106.
    Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Marto S, RastogP, Gralow J, Swa SM, Wer EP, Colon-Otero G, Davson NE, Mamounas E, ZujewskJA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epermal growth factor receptor 2-pose breast cancer: planned jot analys of overall surval from NSABP B-31 and NCCTG N9831. J Cl Oncol. 2014 Nov 20;32(33):3744-52. do 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20.
    Chan A, Delaloge S, Holmes FA, Moy B, ata H, Harvey VJ, Robert NJ, SovskT, Gokmen E, von Mckwz G, Ejlertsen B, Ch SKL, MansJ, Barrs CH, Gnant M, Buyse M, Gore Smh J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, nnottN, Rodruez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Mart M; ExteNET Study Group. Nerat after trastuzumab-based adjuvant therapy patnts wh HER2-pose breast cancer (ExteNET): a multentre, randomed, double-bld, placebo-controlled, phase 3 trl. Lancet Oncol. 2016 Mar;17(3):367-377. do 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.
    Rabdran SK, DcafanCM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nakantan R, Overbeek E, Reh MF, Shen R, ShX, Tsou HR, Wang YF, Wsner A. Antumor acty of HK272, an orally acte, reversle hor of the HER-2 tyrose kase. Cancer Res. 2004 Jun 1;64(11):3958-65. do 10.1158/0008-5472.CAN-03-2868.
    Burste HJ, Sun Y, D LY, Jng Z, Paraens R, Tan AR, Awada A, Ranade A, Jo S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R. Nerat, an reversle ErbB receptor tyrose kase hor, patnts wh advanced ErbB2-pose breast cancer. J Cl Oncol. 2010 Mar 10;28(8):1301-7. do 10.1200/JCO.2009.25.8707. Epub 2010 Feb 8.
    Mart M, Bonneterre J, Geyer CE Jr, o Y, Ro J, Lang K SB, Germa C, Vermette J, Wang K, Wang K, Awada A. A phase two randomed trl of nerat monotherapy versus lapat plus capecabe combatn therapy patnts wh HER2+ advanced breast cancer. Eur J Cancer. 2013 Dec;49(18):3763-72. do 10.1016/j.ejca.2013.07.142. Epub 2013 Aug 15.
    Castro JG, Ch-Beckford N. Crofelemer for the symptomat relf of non-fectus drrhea adult patnts wh H/AS on antretroval therapy. Expert Rev Cl Pharmacol. 2015;8(6):683-90. do 10.1586/17512433.2015.1082424. Epub 2015 Aug 27.
    Tradtrant L, Namkung W, Verkman AS. Crofelemer, an antecretory antrrheal proanthocyan olomer extracted from Croton lechler targets two dtct testal chlore channels. Mol Pharmacol. 2010 Jan;77(1):69-78. do 10.1124/mol.109.061051. Epub 2009 Oct 6.
    Crutchley RD, Mler J, Garey KW. Crofelemer, a novel agent for treatment of secretory drrhea. Ann Pharmacother. 2010 May;44(5):878-84. do 10.1345/aph.1M658. Epub 2010 Apr 13.
    Macarthur RD, Hawks TN, Brown SJ, Lamarca A, Clay PG, Barrett AC, Bortey E, Paterson C, Golden PL, Forbes WP. Effacy and safety of crofelemer for nonfectus drrhea H-seropose duals (ADVENT trl): a randomed, double-bld, placebo-controlled, two-stage study. H Cl Trls. 2013 Nov-Dec;14(6):261-73. do 10.1310/hct1406-261.
    An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab

  6. 6
    تقرير

    المساهمون: Val J. Lowe

    المصدر: Diphenoxylate / Atropine to Decrease Bowel Activity During F-18 FDG PET

  7. 7
  8. 8
  9. 9
  10. 10